features of importance in predicting lack of benefit from enzyme replacement by erythrocyte infusion in ada-negative severe combined immunodeficiency appear to be early clinical presentation with associated severe skeletal abnormalities , a very low level of residual ada activity in peripheral blood mononuclear cells , and lack of effect of exogenous ada on the absent in vitro mitogen response of ada-negative blood mononuclear cells .
C0085110
severe combined immunodeficiency
C0001457
ada